Quick answer
Renji Hospital in Shanghai has completed the full course of CT041 (satri-cel) — collection of a patient's immune cells, manufacturing, infusion and the first imaging assessment — for three people with advanced gastric cancer, and says it is now the centre worldwide that has taken the most patients through both steps since the drug was approved [1]. All three were assessed as stable disease on that first scan. CT041 is described as the world's first CAR-T product approved for a solid tumour, and it works only in patients whose tumour tests positive for a protein called Claudin18.2 [2][3].
Key takeaways
- Three patients at Renji completed the whole pathway — cell collection, manufacturing, infusion and first imaging assessment — outside a clinical trial, and all three were reported as stable disease at first assessment [1].
- Stable disease means the cancer had not grown on that scan. It is not the same as the tumour shrinking, and no response rates were published for these three [1].
- CT041 (satri-cel, 舒瑞基奥仑赛注射液) is described as the first CAR-T product approved anywhere for a solid tumour; it is targeted at Claudin18.2-positive advanced gastric or gastro-oesophageal junction cancer [2][3].
- In the pivotal phase II trial published in The Lancet, the objective response rate was 41%, disease control 81%, and median overall survival 9.17 months [2][4].
- Eligibility is narrow: Claudin18.2-positive by immunohistochemistry (≥40% of tumour cells scoring 2+/3+), HER2-negative, and at least two earlier lines of treatment already failed [2].
The condition in context: advanced gastric cancer, where options run out
Stomach cancer is usually found late. By the time it causes symptoms that send someone to a doctor, it has often already spread, and surgery — the only treatment that can cure it — is no longer an option. Chemotherapy, targeted drugs and immunotherapy can hold it back for a while, but almost everyone eventually runs out of lines of treatment.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | About 1,089,000 new stomach cancer cases and 660,000 deaths from it in 2022. | IARC GLOBOCAN 2022, as tabulated by Duke Kunshan University Global Health Research Center [5] |
| China | 478,000 new stomach cancer cases in 2022 — 43.9% of the world's total — and 373,000 deaths, or 56.5% of the world's stomach cancer deaths. Five-year survival across all cancers: 43.7%. | IARC GLOBOCAN 2022 and national data, as tabulated by Duke Kunshan [5] |
| Japan | Age-standardised cancer incidence of 248.0 per 100,000, with five-year cancer survival of 64.1% — a useful comparison because stomach cancer is common in East Asia and Japan screens for it widely. | Five-country comparison compiled from CONCORD and IARC data, Duke Kunshan [5] |
| United States | Age-standardised cancer incidence of 362.2 per 100,000 and five-year cancer survival of 67.2%; early-stage diagnosis rates exceed 70% for some common cancers. | Same five-country comparison [5] |
The gap in those survival figures is mostly about stage at diagnosis, not about treatment quality: countries that find stomach cancer early do better with the same drugs. That is the background to why cell therapy matters here — for patients already diagnosed late, with several lines of treatment behind them, the remaining options are measured in months. China is also one of the countries with the largest number of registered CAR-T studies, so a share of the experimental work in this area is happening there [5].
CAR-T itself is not new. For more than ten years it has produced striking results in leukaemia and lymphoma, which are cancers of the blood. Solid tumours resisted it for three reasons, as Renji's own specialists put it: finding a target that is on the tumour but not on healthy tissue, getting the modified cells physically into a solid mass, and making the effect last [2].
What happened
Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, was among the first hospitals in China to offer CT041 after its approval. In July 2026 its oncology team, led by Xiao Xiuying, collected immune cells from the first two patients; by 22 July the number had reached four [2][3][4].
By mid-October the team reported that three patients had been through the entire pathway — collection, manufacturing, infusion and the first imaging assessment — and that Renji had become the centre worldwide with the most patients to reach both milestones since the drug came to market [1].
The department itself is a large one: Renji's oncology department is a municipal key clinical discipline in Shanghai, ranked first among municipal hospitals for departmental competitiveness in 2022 and third among general hospitals for oncology in the 2023 science-and-technology evaluation, with 15 tumour multidisciplinary teams and nine joint clinics [3][4]. Xiao led the drafting of the Chinese Anti-Cancer Association's national guidance on Claudin18.2-targeted treatment [2].
CAR-T is short for chimeric antigen receptor T-cell therapy. Doctors take a patient's own T cells — the immune cells that kill infected or abnormal cells — and give them a new receptor, a kind of homing device, that recognises a specific protein on the tumour. The cells are grown in a laboratory and infused back. In CT041 the target is Claudin18.2, a protein that is concentrated in gastric tumour tissue but present in only a limited range of normal tissue, which is what makes it usable as a target [2]. Only patients whose tumour expresses enough of it are eligible.
The case as reported
The details below come from the hospital and the Chinese-language reports of it; they are the hospital's account, not an independent review.
One of the three patients had been diagnosed with widespread spread to the lining of the abdomen. She had already been through several lines of chemotherapy, targeted therapy and immunotherapy, and the disease had kept progressing. She had developed large-volume ascites — fluid building up in the abdomen — and a partial bowel obstruction, and was living with two tubes in place: one to drain the abdomen and one passed through the nose to decompress the bowel. She could not eat normally and was on nutritional support [1].
After CAR-T and supportive treatment, both tubes were removed and she returned to eating normally. Her family sent a message of thanks to the team. Renji describes this as the point of the treatment: not a scan measurement, but being able to eat again [1]. No follow-up beyond the first assessment has been published.
Why it matters for people considering care in China
| What it tells you | What it does not tell you |
|---|---|
| The drug has moved out of trials: patients are being treated through a standard clinical pathway, not a study protocol [1][3]. | Anything about outcomes for these three patients beyond "stable disease" on one scan. |
| Renji has a defined pathway covering targeting tests, multidisciplinary assessment, collection, infusion, monitoring and complication management [2]. | Whether you would be eligible: that depends on your tumour's Claudin18.2 result and treatment history. |
| Trial results give a sense of scale: 41% responded, 81% had disease control, median survival 9.17 months [2][4]. | Whether those figures will hold in routine use, in patients who would not have met trial criteria. |
Availability and limits
- Eligibility is narrow. Claudin18.2-positive by immunohistochemistry at ≥40% of tumour cells scoring 2+/3+, HER2-negative, and at least two prior lines of treatment failed [2]. Most people with gastric cancer will not qualify.
- Three patients is not evidence. "Stable disease" at first assessment in three people tells you the pathway can be delivered; it does not tell you how often the treatment works.
- Manufacturing takes weeks. Cells take roughly three to four weeks to prepare, during which the disease can progress; patients may need bridging treatment [2].
- There are real risks. Cytokine release syndrome, low blood counts and gastrointestinal reactions are among the complications the team says it monitors for [2].
- Cost and access for international patients are not published. None of the sources we read gives a price or says whether non-residents can be treated. Ask the hospital directly.
What to ask before booking anything
| Question | Why it matters |
|---|---|
| Can you test my existing tumour tissue for Claudin18.2, or do I need a new biopsy? | Without a positive result there is no route to this treatment at all. |
| Do you treat patients who are not Chinese residents, and how long would the whole pathway take in-country? | Cell manufacturing plus monitoring means weeks, not days. |
| What is the total cost, including hospital stay and complication management? | Cell therapies are expensive and complications add to the bill. |
| How many patients have you treated, and what have the outcomes been? | Three reported cases do not establish a success rate. |
| Which department and language support would be available? | Language support is usually confirmed for an international office, not each department. |
Questions patients ask
What is CAR-T therapy?
It is a treatment that uses a patient's own immune cells. T cells are taken out, given a new receptor that recognises a protein on the cancer, grown in a laboratory, and infused back to attack the tumour. Xiao Xiuying describes it as fitting the immune cells with a navigation system [2].
What is Claudin18.2, and why does it matter?
It is a protein found in high concentrations on many gastric cancer cells and in only a limited range of normal tissue, which is what makes it usable as a target. CT041 only works in patients whose tumour expresses enough of it — defined as at least 40% of tumour cells scoring 2+ or 3+ on immunohistochemistry [2].
Does "stable disease" mean the treatment worked?
It means the cancer had not grown at the first assessment after infusion. It is a meaningful result in advanced cancer, but it is not tumour shrinkage and it is not a remission. No response data for these three patients has been published [1].
How long does the whole process take?
Roughly three to four weeks for the cells to be manufactured, during which the disease may need bridging treatment, plus assessment before infusion and monitoring afterwards for complications such as cytokine release syndrome [2].
Can someone from outside China be treated with CT041?
We could not find any published statement on this. Ask Renji's international office directly, and ask for the eligibility testing, the timetable and the total cost in writing before making travel plans.